1 citations
,
March 2024 in “Journal of Cellular and Molecular Medicine” In this study, researchers found that 4-Octyl itaconate (4-OI) inhibited cisplatin-induced ferroptosis and protected auditory cells by activating the NRF2/HO-1 signaling pathway, suggesting a potential therapeutic approach for reducing hearing loss associated with cisplatin treatment.
17 citations
,
April 2021 in “Frontiers in Pharmacology” This review discusses the role of Nrf2 in hearing loss and its potential as a target for developing hearing protection drugs, but reports no new clinical results.
8 citations
,
June 2021 in “International Journal of Molecular Sciences” In this study, UCMSC exosomes showed protective effects against cisplatin-induced hearing loss in mice by improving hearing and promoting cochlear tissue repair.
May 2024 in “Biochemical pharmacology” This study found that targeting CISD1 with the compound NL-1 reduced mitochondrial dysfunction and reactive oxygen species accumulation, protecting against cisplatin-induced hearing loss in cell models and mice, without affecting cisplatin's cancer-fighting effectiveness.
52 citations
,
May 2011 in “APOPTOSIS” In this study, cisplatin was found to induce cell death in human hair follicle cells through hydroxyl radical generation and Bcl-2 down-regulation, suggesting potential strategies for preventing chemotherapy-induced alopecia.